Given the aggressive coagulopathy associated with APL (85% of cases) [7], it is imperative that cryptic PML::RARA translocations are identified early to initiate ATRA/ATO given the resistance of APL to standard induction chemotherapy regimens. The gene discussed is RARA; the disease is acute promyelocytic leukemia.